194 related articles for article (PubMed ID: 28432037)
1. Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy.
Hodgins NO; Al-Jamal WT; Wang JT; Klippstein R; Costa PM; Sosabowski JK; Marshall JF; Maher J; Al-Jamal KT
J Control Release; 2017 Jun; 256():141-152. PubMed ID: 28432037
[TBL] [Abstract][Full Text] [Related]
2. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
Hodgins NO; Wang JT; Al-Jamal KT
Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
[TBL] [Abstract][Full Text] [Related]
3. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
[TBL] [Abstract][Full Text] [Related]
4. Organ Biodistribution of Radiolabelled γδ T Cells Following Liposomal Alendronate Administration in Different Mouse Tumour Models.
Wang JT; Hodgins NO; Al-Jamal WT; Maher J; Sosabowski JK; Al-Jamal KT
Nanotheranostics; 2020; 4(2):71-82. PubMed ID: 32190534
[TBL] [Abstract][Full Text] [Related]
5. Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Whilding LM; Parente-Pereira AC; Zabinski T; Davies DM; Petrovic RMG; Kao YV; Saxena SA; Romain A; Costa-Guerra JA; Violette S; Itamochi H; Ghaem-Maghami S; Vallath S; Marshall JF; Maher J
Mol Ther; 2017 Jan; 25(1):259-273. PubMed ID: 28129120
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
[TBL] [Abstract][Full Text] [Related]
7. Alendronate liposomes for antitumor therapy: activation of γδ T cells and inhibition of tumor growth.
Gutman D; Epstein-Barash H; Tsuriel M; Golomb G
Adv Exp Med Biol; 2012; 733():165-79. PubMed ID: 22101722
[TBL] [Abstract][Full Text] [Related]
8. The integrin αvβ6: a novel target for CAR T-cell immunotherapy?
Whilding LM; Vallath S; Maher J
Biochem Soc Trans; 2016 Apr; 44(2):349-55. PubMed ID: 27068939
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Bi-Terminal PEGylation of an Integrin αvβ₆-Targeted ¹⁸F Peptide on Pharmacokinetics and Tumor Uptake.
Hausner SH; Bauer N; Hu LY; Knight LM; Sutcliffe JL
J Nucl Med; 2015 May; 56(5):784-90. PubMed ID: 25814519
[TBL] [Abstract][Full Text] [Related]
10. In Vivo PET Tracking of
Man F; Lim L; Volpe A; Gabizon A; Shmeeda H; Draper B; Parente-Pereira AC; Maher J; Blower PJ; Fruhwirth GO; T M de Rosales R
Mol Ther; 2019 Jan; 27(1):219-229. PubMed ID: 30429045
[TBL] [Abstract][Full Text] [Related]
11. A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.
Eberlein C; Kendrew J; McDaid K; Alfred A; Kang JS; Jacobs VN; Ross SJ; Rooney C; Smith NR; Rinkenberger J; Cao A; Churchman A; Marshall JF; Weir HM; Bedian V; Blakey DC; Foltz IN; Barry ST
Oncogene; 2013 Sep; 32(37):4406-16. PubMed ID: 23108397
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Two Optical Probes for Imaging the Integrin α
Ganguly T; Tang SY; Bauer N; Sutcliffe JL
Mol Imaging Biol; 2020 Oct; 22(5):1170-1181. PubMed ID: 32002763
[TBL] [Abstract][Full Text] [Related]
13. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.
Kabelitz D; Wesch D; Pitters E; Zöller M
J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170
[TBL] [Abstract][Full Text] [Related]
14. DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
Chang Q; Geng R; Wang S; Qu D; Kong X
Drug Deliv; 2016 Nov; 23(9):3629-3638. PubMed ID: 27749106
[TBL] [Abstract][Full Text] [Related]
15. High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6.
Saha A; Ellison D; Thomas GJ; Vallath S; Mather SJ; Hart IR; Marshall JF
J Pathol; 2010 Sep; 222(1):52-63. PubMed ID: 20629113
[TBL] [Abstract][Full Text] [Related]
16. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
Gray BP; McGuire MJ; Brown KC
PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.
Zhu X; Li J; Hong Y; Kimura RH; Ma X; Liu H; Qin C; Hu X; Hayes TR; Benny P; Gambhir SS; Cheng Z
Mol Pharm; 2014 Apr; 11(4):1208-17. PubMed ID: 24524409
[TBL] [Abstract][Full Text] [Related]
19. PET/CT Imaging of NSCLC with a α
Flechsig P; Lindner T; Loktev A; Roesch S; Mier W; Sauter M; Meister M; Herold-Mende C; Haberkorn U; Altmann A
Mol Imaging Biol; 2019 Oct; 21(5):973-983. PubMed ID: 30671741
[TBL] [Abstract][Full Text] [Related]
20. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z
ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
